Story preview
Continue reading on the publisher site for the full article.
Read on publisher →Stock Titan
News Atlas is free and independent. If it’s useful to you, you can support it with a coffee. ☕ Buy me a coffee
Coverage
Tone
Outlets covering it
5
in the last 3 days
First reported
6 days ago
4 outlets since
Countries
4 other outlets reported this story in the last 3 days.
Weltruza, the first subcutaneous long-acting injectable (LAI) formulation of olanzapine, requires no loading doses, oral supplementation, or postinjection monitoring.
The global SGLT 2 Inhibitors market is entering a more competitive phase as expanding cardiovascular and kidney disease applications coincide with the arrival of generic medicines in major pharmaceutical markets On April 7 2026 the U S Food and Drug ...